Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesAdministrative/Operational PolicyIntegrated Home Care Transition Coverage | OpenPay…
    Ask Trek AI about this page
    CurrentIntegrated Home Care ServicesPolicy H2237_GHHMQVREN_C

    2027 Transition Policy for Independent Care Health Plan Prescription Drug Coverage

    Customize your policy alerts

    Sign up for integrated_home_care_services Policy H2237_GHHMQVREN_C alerts

    Get alerted when Policy H2237_GHHMQVREN_C changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Governs temporary Medicare Part D prescription drug coverage when a drug is not on the approved list or is subject to prior authorization, quantity limits, or step therapy, including transition, exception, and appeal situations.

    Policy Summary
    PayerIntegrated Home Care Services
    Policy2027 Transition Policy for Independent Care Health Plan Prescription Drug Coverage
    Policy CodePolicy H2237_GHHMQVREN_C
    Change TypeNo material change
    Effective DateJan 1, 202745d
    Next Review DateN/A
    Key ActionFor eligible Medicare Part D drugs, provide the applicable temporary transition supply and send the member and prescriber notice within 3 business days after the first fill.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    90 daysInitial transition period
    30 daysStandard transition supply
    31 daysLong-term-care or setting-change supply
    108 daysMinimum claim history

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    180 daysDrug-history look-back
    72 / 24 hoursException decision timeframes

    Transition Coverage and Member Access

    Eligible Transition Coverage

    Transition coverage is available when the member meets the applicable eligibility and treatment-setting criteria below.

    ALL of the following

    • The drug is covered by Medicare Part D.
    • ONE of the following member or treatment-setting circumstances applies

      • The member is new to the plan or is an existing member with a history of using the drug: during the first 90 days as a member, cover a 30-day supply one time per drug. If the prescription is written for less than 30 days, allow multiple fills totaling up to 30 days.
      • The member is new to a long-term-care facility and meets the applicable long-term-care conditions

        • The member is new to the plan.
        • The member has both Medicare and full Medicaid benefits.
        • During the first 90 days as a member, cover a 31-day supply. If the prescription is written for less than 31 days, allow multiple fills totaling up to 31 days.
        • After the first 90 days, cover a 31-day emergency supply while an exception request or advance-approval request is reviewed. If the prescription is written for less than 31 days, allow multiple fills totaling up to 31 days.
      • The member changes treatment settings during the plan year

        • Moves from a hospital or skilled nursing facility to a home setting.
        • Moves from a home setting to a hospital or skilled nursing facility.
        • Moves from one skilled nursing facility to another and needs a new pharmacy.
        • Stops staying at a skilled nursing facility where Medicare Part A covered the prescription drugs and now needs Medicare Part D.
        • Gives up Hospice status and now needs Medicare Parts A and B.
        • Leaves a long-term psychiatric hospital where drugs were tailored to the member.

    Treatment-setting transition supply

    • For a qualifying treatment-setting change, cover up to a 31-day supply when the drug is obtained at a pharmacy.
    • If the member changes treatment settings more than once in the same month, the member may need to request an exception or advance approval.
    • Review the request to determine whether the member has a treatment plan and whether changing it would harm the member's health.

    Transition Exclusions and Medical Review

    A transition supply does not apply to the following categories. After a Part D transition supply, the plan may also require medical review.

    Transition exclusions

    • The drug requires a determination of whether coverage is under Medicare Part A or Part B rather than Part D.
    • The drug may not be eligible for Medicare Part D coverage; the plan may need to know what the drug is being used to treat before coverage can be determined.
    • The drug requires information to determine whether it is being used safely.

    Medical review after a Part D transition supply

    • The drug is not on the plan's approved list, or the plan requires advance approval.
    • The applicable advance-approval condition applies

    Exceptions, Appeals, and Continued Access

    Members and prescribers should pursue an exception, advance approval, or an appeal when continued coverage is needed after a transition fill.

    Transition notices and next steps

    • After a transition fill, send the member and the member's doctor a letter within 3 business days. For the first transition fill, send letters only if the transition supply was provided in multiple fills.
    • The letter must explain that additional drug coverage will not be provided unless the plan approves an exception or approves the drug in advance.
    • The member and prescriber may review the Prescription Drug Guide and consider a covered alternative, request an exception, or request advance approval.

    Exception request

    • The member must ask the doctor to send a letter explaining that the drug is needed to treat the health problem because covered drugs would not work as well or would harm the member's health.

    Transition-Supply Cost Sharing

    Cost sharing for a transition supply depends on whether the member receives the low-income subsidy.

    ONE of the following applies

    • The member receives the low-income subsidy (LIS, also called Extra Help): the amount paid for a 30-day supply must be no more than the member's LIS limit.
    • The member does not receive Extra Help: the amount paid for a 30-day supply is based on the plan's terms; refer to the Member Handbook for those terms.

    Supply Quantities, Timing, and Operational Thresholds

    Standard initial transition period
    PeriodFirst 90 days of membership
    Applies toNew members and existing members with a history of the drug
    Coverage contexti Care covers a Medicare Part D drug during this initial transition period
    Standard transition quantity
    Quantity30 days total per drug
    FrequencyOne time per drug
    Shorter prescriptionsMultiple fills are allowed when the prescription is written for less than 30 days, up to a total of 30 days

    Operational Requirements for Transition Processing

    Prior Authorization

    Evaluate transition-supply eligibility

    Identify drugs that are not on the approved list or are subject to quantity limits, step therapy, or other prior authorization requirements, and evaluate whether a transition supply is available.

    Denial Risk

    Apply transition-supply exclusions

    Do not provide a transition supply when coverage responsibility between Medicare Part A, Part B, and Part D must be determined, when the drug may not be eligible for Part D coverage, or when information is needed to determine whether the drug is being used safely.

    Key Policy Terms

    Transition supply
    MeaningA temporary supply of a drug that a member can continue receiving
    Formulary statusThe drug is not on the approved list
    RestrictionsThe drug may be subject to prior authorization, quantity limits, step therapy, or required clinical information
    Brand-new drug
    MeaningA drug for which i Care cannot determine at the point of sale whether treatment is beginning or ongoing
    History reviewi Care uses claim history to determine whether the member has an ongoing treatment history
    History threshold
    Policy Summary
    PayerIntegrated Home Care Services
    Policy2027 Transition Policy for Independent Care Health Plan Prescription Drug Coverage
    Policy CodePolicy H2237_GHHMQVREN_C
    Change TypeNo material change
    Effective DateJan 1, 202745d
    Next Review DateN/A
    Key ActionFor eligible Medicare Part D drugs, provide the applicable temporary transition supply and send the member and prescriber notice within 3 business days after the first fill.
    SourceLink
    On This Page
    Transition Coverage and Member AccessSupply Quantities, Timing, and Operational ThresholdsOperational Requirements for Transition ProcessingKey Policy Terms
    • There are limits on the amount the member can receive.
    • The member must try a less costly drug first.
    • The plan needs additional facts about the member's health.
  1. The letter must explain why the plan's drug limit does not fit the member's health problem or would harm the member's health.
  2. For a standard request, provide the decision no more than 72 hours after receiving the doctor's letter.
  3. Grant a fast request when the plan finds, or the doctor states, that waiting for a standard request could harm the member's life, health, or ability to function; provide the decision no more than 24 hours after receiving the doctor's letter.
  4. If the exception is denied

    • The member may ask whether another drug is covered for the health problem when the requested drug is not on the approved list or is subject to advance approval, step therapy, or quantity limits.
    • The member should ask the doctor whether the alternative drug is an appropriate choice.
    • The member may appeal the decision no more than 65 days after the plan's first decision.

    Continued access during review

    • The plan may extend the transition supply while reviewing an appeal or an exception request.
    • For a new member in a long-term-care facility after the initial 90-day period, provide a 31-day emergency supply while reviewing an exception request or advance-approval request.
    Long-term-care initial transition quantity
    Quantity31 days total per drug
    Applies toNew members in a long-term-care facility who have Medicare and full Medicaid benefits
    Shorter prescriptionsMultiple fills are allowed when the prescription is written for less than 31 days, up to a total of 31 days
    Long-term-care emergency supply
    Quantity31 days total
    TimingAfter the initial 90-day period
    Shorter prescriptionsMultiple fills are allowed when the prescription is written for less than 31 days, up to a total of 31 days
    Treatment-setting transition quantity
    QuantityUp to 31 days per drug
    LocationAt a pharmacy
    Applies whenA member changes treatment settings during the plan year
    Ongoing-drug history threshold
    Minimum historyAt least 108 days of i Care claim history
    PurposeTo determine whether the member has an ongoing history of the drug
    Point of saleUsed when i Care cannot distinguish a brand-new drug from ongoing treatment at the point of sale
    Drug-history look-back
    Look-back period180 days
    Starting pointThe member effective date or the start of the plan year
    PurposeTo review drug history and distinguish ongoing treatment from a brand-new drug
    Transition notice timeframe
    Notice deadlineWithin 3 business days after the first transition fill
    RecipientsThe member and the member’s doctor
    Multiple fillsFor a supply provided in multiple fills, letters are sent for the first transition fill only
    Exception decision timeframes
    Standard requestDecision no more than 72 hours after receiving the doctor’s letter
    Expedited requestDecision no more than 24 hours after receiving the doctor’s letter
    Expedited criterionAvailable when waiting for a standard request could harm the member’s life, health, or ability to function
    Appeal filing timeframe
    Filing deadlineNo more than 65 days after the initial decision
    ActionThe member may ask i Care to review the exception decision
    After a denialThe member may also ask whether another covered drug is available
    Billing Rule

    Provide temporary transition coverage

    For eligible Medicare Part D drugs, support a one-time 30-day supply during the first 90 days of membership. Provide a 31-day supply for qualifying new long-term-care members and up to 31 days when a member changes treatment settings; allow multiple shorter fills to reach the applicable total-day supply.

    Documentation Required

    Handle contract-year and drug-history transitions

    Apply transition processes across contract years for existing members affected by negative formulary changes and for members enrolling with November 1 or December 1 effective dates. Use at least 108 days of i Care claim history within a 180-day look-back to distinguish ongoing drug use from a brand-new drug.

    Prior Authorization

    Maintain access during exception or appeal review

    Continue or extend temporary coverage while an exception request or appeal is reviewed. For a qualifying new long-term-care member, provide a 31-day emergency supply after the initial 90-day transition period; when treatment settings change more than once in the same month, evaluate an exception or prior authorization request.

    Documentation Required

    Send transition notices and obtain clinical information

    After the first transition fill, send notice to the member and prescriber within 3 business days and explain that additional coverage requires approval. Obtain clinical information from the prescriber when needed to evaluate an exception or prior authorization request.

    Prior Authorization

    Process formulary exception requests

    For an exception request, require a prescriber letter explaining why covered alternatives would not work as well or would harm the member and why an applicable quantity limit is inappropriate or harmful. Decide within 72 hours for a standard request or within 24 hours for an expedited request when delay could harm the member’s life, health, or ability to function.

    Denial Risk

    Support alternatives and appeals

    When an exception is denied, identify potentially covered alternatives and allow the member to appeal the decision no more than 65 days after the initial decision. The member should ask the prescriber whether an alternative drug is a good choice.

    At least 108 days of i Care claim history within the applicable look-back period
    LIS / Extra Help
    MeaningThe low-income subsidy, also called Extra Help
    Cost-sharing limitThe member’s cost for a 30-day supply will be no more than the applicable LIS limit
    Plan yearThe stated cost-sharing protection applies in 2027
    Exception
    MeaningA request for coverage of a non-formulary drug or an exception to a formulary restriction
    Clinical basisCovered drugs would not work as well or would harm the member’s health
    Quantity-limit basisThe applicable quantity limit is not fitting for the member’s health problem or would harm the member’s health